“Point of Care” T cell therapy
Adheren’s ACC process only takes one hour. The process of T cell isolation, modification, and infusion can be done in a single machine in the hospitals without days of T cell engineering and expansion. This technology benefits patients significantly by reducing the time and cost of T cell therapy.
Compatible with existing antibodies
The technology is ready today for application to any existing IgG1 antibodies, which will significantly shortens the R&D time and cost. The Antibody-Cell Conjugation (ACC) platform can transform an existing antibody therapy directly into a T cell immunotherapy.
No genetic engineering of T cells
T-PICK greatly increases T-cell therapy’s safety profile, and eliminates the safety concern of genetically engineered T cells. In addition, T- PICK greatly reduce the R&D and manufacture cost compared to genetically engineered T cells, and has no viral transduction processes.